Avalo Therapeutics
AVTXNASDAQUSD
- Source valuation snapshot. Not a live recalculation.
- Latest filed annual earnings; price snapshot date unavailable. Not forward P/E.
- Diluted earnings per share from the latest filed annual.
- $7.16 Prior regular-session close from the quote source.
- $7.17–$8.55 Regular-session low and high so far today.
- 1.8M Regular-session shares traded · Nov 11, 4:00 PM ET.
- Jan 11 projected Projected for 2027-01-11 from the company’s own results filings (SEC 8-K Item 2.02). The company has not confirmed the date.
- $6.53–$24.27 52-week trading low and high returned by the quote source.
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
The core investment thesis
Own AVTX if abdakibart turns IL-1 inhibition into clearly differentiated hidradenitis suppurativa data before the cash burn and dilution risk overwhelm the option value.
AVTX price history
Loading recent earnings…
Investment thesis
What must happen next
Abdakibart’s IL-1 biology must translate into a clinically differentiated HS signal in LOTUS; otherwise Avalo has no commercial engine to replace the development spend.HoldingMateriality: High
FY2025 GAAP operating income was -$72.925 million, reflecting a company investing heavily ahead of the LOTUS readout rather than generating operating profit. If this holds, the company owns a credible Phase 3-ready asset; if it breaks, most of the enterprise value becomes hard to justify.
Watch: LOTUS fails to show a placebo-adjusted HiSCR75 response that suggests superiority or meaningful differentiation versus adalimumab, secukinumab, or bimekizumab.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
FY2025 GAAP operating income was -$72.925 million, reflecting a company investing heavily ahead of the LOTUS readout rather than generating.
Open source ↗HS demand can support a valuable biologic only if the unmet need Avalo identifies remains real after currently approved biologics mature and compete.StrengtheningMateriality: High
FY2025 annual GAAP revenue was only $59 thousand, confirming Avalo’s value is tied to future HS development rather than legacy product sales. If current therapies leave a large refractory population, successful abdakibart data can command strategic value; if existing drugs solve more of the market, Avalo’s upside narrows.
Watch: UCB’s bimekizumab or Novartis’s secukinumab produces long-term HS durability data that meaningfully reduces the residual unmet need.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
FY2025 annual GAAP revenue was only $59 thousand, confirming Avalo’s value is tied to future HS development rather than legacy.
Open source ↗Avalo’s focused model creates value only if its cash runway carries abdakibart through the LOTUS readout and Phase 3 decision without a distressed financing.HoldingMateriality: Medium
MD&A states cash, cash equivalents, and short-term investments were $98.3 million at December 31, 2025 and were expected to fund operations into 2028. If runway is sufficient, shareholders keep more of the clinical upside; if not, dilution can absorb the value of even decent data.
Watch: A positive LOTUS result forces rapid Phase 3 startup, manufacturing scale-up, or longer safety work before a partner is secured.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
MD&A states cash, cash equivalents, and short-term investments were $98.3 million at December 31, 2025 and were expected to fund.
Open source ↗Because Avalo has no self-funding commercial business, operating burn must remain tied to abdakibart clinical and CMC progress rather than drifting into unfocused overhead or unrelated assets.HoldingMateriality: Medium
FY2025 annual operating cash flow was -$51.458 million, up from -$49.056 million in FY2024 and -$30.680 million in FY2023. Disciplined burn preserves option value; unfocused spending lowers the probability that each dollar creates per-share clinical value.
Watch: Management in-licenses a second major program before abdakibart has generated proof-of-concept data.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
FY2025 annual operating cash flow was -$51.458 million, up from -$49.056 million in FY2024 and -$30.680 million in FY2023.
Open source ↗Indication expansion and out-licensing can add upside only if HS validates abdakibart as a differentiated IL-1 asset; otherwise broader pipeline optionality becomes a cash-consuming distraction.HoldingMateriality: Medium
FY2025 annual GAAP net income was -$78.259 million, showing that optionality is being funded through losses rather than operating cash generation. Successful HS proof can turn Avalo from a single trial story into a platform-like inflammation asset; failed proof leaves limited strategic leverage.
Watch: LOTUS does not establish enough HS differentiation for partners to fund or validate additional indications.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
FY2025 annual GAAP net income was -$78.259 million, showing that optionality is being funded through losses rather than operating cash.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
Abdakibart’s IL-1 biology must translate into a clinically differentiated HS signal in LOTUS; otherwise Avalo has no commercial engine to replace the development spend. If this holds, the company owns a credible Phase 3-ready asset; if it breaks, most of the enterprise value becomes hard to justify.
HS demand can support a valuable biologic only if the unmet need Avalo identifies remains real after currently approved biologics mature and compete. If current therapies leave a large refractory population, successful abdakibart data can command strategic value; if existing drugs solve more of the market, Avalo’s upside narrows.
Avalo’s focused model creates value only if its cash runway carries abdakibart through the LOTUS readout and Phase 3 decision without a distressed financing. If runway is sufficient, shareholders keep more of the clinical upside; if not, dilution can absorb the value of even decent data.
Because Avalo has no self-funding commercial business, operating burn must remain tied to abdakibart clinical and CMC progress rather than drifting into unfocused overhead or unrelated assets. Disciplined burn preserves option value; unfocused spending lowers the probability that each dollar creates per-share clinical value.
Indication expansion and out-licensing can add upside only if HS validates abdakibart as a differentiated IL-1 asset; otherwise broader pipeline optionality becomes a cash-consuming distraction. Successful HS proof can turn Avalo from a single trial story into a platform-like inflammation asset; failed proof leaves limited strategic leverage.
All standing thesis claims
Original report summary
abdakibart turns IL-1 inhibition into clearly differentiated hidradenitis suppurativa data before the cash burn and dilution risk overwhelm the option value.
Bull case and bear case
Bull case and bear case for Avalo Therapeutics
Where the evidence on Avalo Therapeutics stands: Holding on the latest evidence (Oct 15, 2026). Of its 5 thesis points, 1 strengthening and 4 holding.
Bull case: what the evidence supports
Abdakibart’s IL-1 biology must translate into a clinically differentiated HS signal in LOTUS; otherwise Avalo has no commercial engine to replace the development spend.
HS demand can support a valuable biologic only if the unmet need Avalo identifies remains real after currently approved biologics mature and compete.
Avalo’s focused model creates value only if its cash runway carries abdakibart through the LOTUS readout and Phase 3 decision without a distressed financing.
Because Avalo has no self-funding commercial business, operating burn must remain tied to abdakibart clinical and CMC progress rather than drifting into unfocused overhead or unrelated assets.
Indication expansion and out-licensing can add upside only if HS validates abdakibart as a differentiated IL-1 asset; otherwise broader pipeline optionality becomes a cash-consuming distraction.
Bear case: what would count against it
LOTUS fails to show a placebo-adjusted HiSCR75 response that suggests superiority or meaningful differentiation versus adalimumab, secukinumab, or bimekizumab.
UCB’s bimekizumab or Novartis’s secukinumab produces long-term HS durability data that meaningfully reduces the residual unmet need.
A positive LOTUS result forces rapid Phase 3 startup, manufacturing scale-up, or longer safety work before a partner is secured.
Thesis-Break Engine
Thesis-break watch · Avalo Therapeutics
No break has crossed Avalo Therapeutics’s thesis. Its break conditions are checked against every new filing as it lands.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MixedReported results of operations (earnings release).
Avalo Therapeutics filed an SEC 8-K on 2026-08-06: Reported results of operations (earnings release). It is a dated development that tests the current thesis.
- MixedDirector or principal officer change.
Avalo Therapeutics filed an SEC 8-K on 2026-06-23: Director or principal officer change. It is a dated development that tests the current thesis.
- MixedOther material event.
Avalo Therapeutics filed an SEC 8-K on 2026-06-16: Other material event. It is a dated development that tests the current thesis.
Risks / falsifiers
What could break the thesis
- LOTUS fails to show a placebo-adjusted HiSCR75 response that suggests superiority or meaningful differentiation versus adalimumab, secukinumab, or bimekizumab.
- UCB’s bimekizumab or Novartis’s secukinumab produces long-term HS durability data that meaningfully reduces the residual unmet need.
- A positive LOTUS result forces rapid Phase 3 startup, manufacturing scale-up, or longer safety work before a partner is secured.
- Management in-licenses a second major program before abdakibart has generated proof-of-concept data.
- LOTUS does not establish enough HS differentiation for partners to fund or validate additional indications.
AVTX news
Loading headlines…
Financial statements
AVTX income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
AVTX: quick answers
- When does Avalo Therapeutics (AVTX) report earnings next?
- Avalo Therapeutics's next results are projected for January 11, 2027, from the dates of its own results filings with the SEC. The company has not confirmed the date. It last reported on November 5, 2026. Earnings calendar
- What is AVTX's short interest?
- As of October 30, 2026, 8.9M AVTX shares were sold short, 15.4% of its shares outstanding, down 25.5% from the count before. At the stock's average daily volume that is 2.1 days to cover. FINRA publishes the count twice a month. AVTX short interest history